This study compared two doses of Proellex, 12.5mg and 25mg, to placebo. The study's primary endpoint was reduction in excessive menstrual bleeding, a common symptom of uterine fibroids.
Women treated with 12.5mg and 25mg of Proellex for three months also experienced an overall highly statistically significant reduction in symptoms associated with uterine fibroids compared to the placebo group. Both doses of Proellex were well tolerated.
“This analysis confirms our interim assessment. Proellex has demonstrated profound effects in relieving symptoms and in improving quality of life in a common and debilitating female disease for which there have been limited drug choices,” commented Joseph Podolski, president and CEO of Repros.